between the new FDA approved drug and the diprivan that was just reinstated to meet U.S shortfalls plus others that are in the pipeline combined with great revenue's with year over year growth the debts being in euros now at 20% discount and counting I'd say the odd are in their favor to meet EBITDA targets plus the insider ownership has all the incentives for them to do so!!